Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05853172 | Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| May 10, 2023 |
| clinicaltrials |
| NCT05844371 | Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery | unknown | Phase 2 | 60 | Yixing People's HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04819971 | Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC | unknown | Phase 2 | 67 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04609176 | Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | unknown | Phase 2 | 64 | Peking UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05052931 | Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 10 | Jianjun YangOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05541146 | Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05769725 | A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer | unknown | Phase 2 | 70 | RenJi HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05750290 | CKD-702 Plus Irinotecan in Gastric Cancer | unknown | Phase 2 | 40 | National Cancer Center, KoreaOTHER_GOV | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03399071 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer(ICONIC) | unknown | Phase 2 | 44 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05720533 | Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 9, 2023 | clinicaltrials |
| NCT03995017 | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma(RiME) | unknown | Phase 1 / Phase 2 | 34 | University of Kansas Medical CenterOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05325528 | Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases | unknown | Phase 2 / Phase 3 | 40 | Zhejiang UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05705635 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | unknown | Phase 2 | 100 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05643677 | Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 47 | Fujian Medical UniversityOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT04077255 | EGFR-targeted Therapy for Gastric Cancer | unknown | Phase 2 | 19 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 30, 2022 | clinicaltrials |
| NCT04893252 | Vactosertib and Durvalumab in Gastric Cancer | unknown | Phase 2 | 55 | Hark Kyun KimOTHER_GOV | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05627414 | Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 25, 2022 | clinicaltrials |
| NCT04744649 | Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial(NICE) | unknown | Phase 2 | 110 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT05608785 | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | unknown | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 0 | Nov 8, 2022 | clinicaltrials |
| NCT05594381 | A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 26, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05545436 | Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer | unknown | Phase 2 | 34 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05528367 | Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | unknown | Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05519202 | Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer | unknown | Phase 2 | 47 | The Central Hospital of Lishui CityOTHER | 0 | Aug 29, 2022 | clinicaltrials |
| NCT05024812 | Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | unknown | Phase 1 / Phase 2 | 64 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05497739 | Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer | unknown | Phase 2 | 68 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05439993 | Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma | unknown | Phase 1 / Phase 2 | 42 | Hallym University Medical CenterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations(FGFR) | unknown | Phase 2 | 80 | LianBio LLCINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05410847 | Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | unknown | Phase 2 | 30 | Hebei Medical UniversityOTHER | 0 | Jun 24, 2022 | clinicaltrials |
| NCT05395780 | A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer | unknown | Phase 2 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05346874 | Neoadjuvant TACiE in Locally Advanced Gastric Cancer | unknown | Phase 2 | 37 | Shanghai Zhongshan HospitalOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT05361161 | Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC) | unknown | Phase 2 | 60 | Gang WuOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05246982 | HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Henlius BiotechINDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT05342389 | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 68 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05313906 | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05311189 | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT04119622 | Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer | unknown | Phase 2 | 30 | Aiping ZhouUNKNOWN | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05270889 | Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial | unknown | Phase 2 | 50 | Yonsei UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05141747 | A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. | unknown | Phase 2 | 60 | Shanghai Miracogen Inc.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04808466 | Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy(WUHIPEC01) | unknown | Phase 2 | 231 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jun 1, 2023source: clinicaltrials